Celebrate Independence Day Safely with Tips from Emergency Physicians
'Every year around the Fourth of July emergency departments see an increase in preventable accidents and injuries,' said Alison Haddock, MD, FACEP, president of ACEP. 'Celebrate responsibly to keep your holiday free of firework-related burns and injuries, heat stroke and other medical emergencies.'
Last year, more than 14,700 people went to the emergency department with injuries from fireworks, according to the Consumer Product Safety Commission. Emergency physicians urge you to mind these firework safety tips:
The CDC estimates that each year, 48 million people get sick from foodborne illnesses. Take these precautions to avoid letting a trip to the emergency department spoil your cookout:
If you are planning to celebrate outside, including visiting the pool, lake, or beach, keep these tips top of mind:
'A little planning and some simple precautions will help you and your family stay safe and healthy on Independence Day,' said Dr. Haddock. 'But if an emergency occurs, there are emergency physicians ready to help you 24/7 every day of the year, even on holidays.'
The American College of Emergency Physicians (ACEP) is the national medical society representing emergency medicine. Through continuing education, research, public education, and advocacy, ACEP advances emergency care on behalf of its 40,000 emergency physician members, and the more than 150 million people they treat on an annual basis. For more information, visit www.acep.org and www.emergencyphysicians.org.
View original content to download multimedia: https://www.prnewswire.com/news-releases/celebrate-independence-day-safely-with-tips-from-emergency-physicians-302494581.html
SOURCE American College of Emergency Physicians
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Ascletis begins dosing in Phase IIa trial of ASC30 for obesity treatment
Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30. The dosing was performed in those identified with at least one weight-related comorbidity. The double-blind, randomised and placebo-controlled trial aims to assess the safety, tolerability, and efficacy of the oral treatment in individuals with a body mass index (BMI) of 30kg/m² or higher, or those overweight with a BMI of at least 27kg/m² but less than 30kg/m². Two oral formulations of the therapy, formulation one (ASC30 tablets) and formulation two (ASC30 tablets A1), both administered once a day, are under evaluation. The mean percentage change in body weight from baseline at week 13 is the trial's primary endpoint. The trial's design incorporates insights from previous Phase Ia and Ib studies, suggesting a lower starting dose and a slower titration strategy for the once-a-day administration of the oral therapy. Its protocol includes a lower starting dose of 1mg of both formulations, and will gradually increase the dosage to maintenance levels of 20mg and 40mg for formulation one, or 20mg, 40mg, and 60mg for formulation two, on a weekly basis. The Phase IIa trial's topline data are anticipated in the fourth quarter of this year. In earlier Phase Ia single ascending dose (SAD) studies, formulation two of ASC30 showed a flatter pharmacokinetic profile compared to formulation one. Ascletis Pharma CEO, chairman and founder Jinzi Jason Wu said: 'We are happy that we are ahead of the schedule of our US 13-week Phase IIa study since we have initiated screening of participants in June and recently completed dosing of the first participants. 'As a small molecule, ASC30 has the potential to offer both once-daily oral and once-monthly subcutaneous injection dosing options for obesity treatment, if approved.' ASC30, the in-house discovery of Ascletis, is a small-molecule glucagon-like peptide-1 receptor (GLP-1R)-biased agonist. This new chemical entity has patent protection in the US and globally until 2044, with no patent extensions. In April 2025, Ascletis reported early weight loss results from a Phase Ib trial of ASC30. "Ascletis begins dosing in Phase IIa trial of ASC30 for obesity treatment" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Chicago Tribune
40 minutes ago
- Chicago Tribune
Daywatch: Once lost, Purple Heart is back with family of Peoria veteran
Good morning, Chicago. Nearly 81 years to the date after 20-year-old Army Pfc. John L. Moore was wounded while fighting to liberate Europe during WWII, the Purple Heart he earned that day is now in the hands of his only surviving sibling. Jerry Moore was little more than a toddler when his brother went off to war. Now 86, Moore held the heart-shaped medal for what he said was the first time after Illinois Treasurer Michael Frerichs presented it to him yesterday at the World War II memorial in Decatur. The poignant ceremony, which included the Macon County Honor Guard, was held just days before the Independence Day holiday weekend. 'It means a lot to my heart,' said Jerry Moore, fighting back tears. 'I don't think there can be any higher honor than getting this back.' Read the full story from the Tribune's Christy Gutowski. Here are the top stories you need to know to start your day, including a look back at a suburban company's role in the creation of DeLorean time machine, why Cook County political leaders are pointing fingers over tech troubles and which Chicago players were named All-Star Game starters. Today's eNewspaper edition | Subscribe to more newsletters | Asking Eric | Horoscopes | Puzzles & Games | Today in History A drive-by mass shooting killed four people and wounded 14 more late last night on the near North Side, Chicago police said. The shooting took place around 11 p.m. yesterday and little detail was available this morning. A large group of people were on the 300 block of West Chicago Avenue when people inside a dark vehicle drove past, fired into the crowd and drove away, police said. The government's top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval of two COVID-19 vaccines, disregarding recommendations from government scientists, according to federal documents released yesterday. The new memos from the Food and Drug Administration show how the agency's vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots from vaccine makers Novavax and Moderna. The Chicago versus downstate dynamic has been a source of friction in state politics for years, and Gov. JB Pritzker's choice figures to play into that issue going forward. For his part, Christian Mitchell said he is ready to meet people from all over Illinois. On the 40th anniversary of the 'Back to the Future' movie premiere, Northbrook-based insurance giant Allstate is traveling back to the past to reveal its little-known role in developing the DeLorean, the futuristic but short-lived, gull-winged, stainless steel car that served as Doc Brown's time machine. Without Allstate, Marty McFly might never have left 1985 or perhaps he would have traveled back in time in a Buick, forever disrupting the space-time continuum of the seminal movie trilogy. Cook County property tax bills already on track to be at least one month tardy may arrive even later as controversial contractor Tyler Technologies' upgrades to the countywide property tax systems are again running behind schedule, leading to mounting frustration and political fighting among county leaders. Cook County Board President Toni Preckwinkle's office yesterday published the first of what is expected to be several reports detailing the technology delays and assigning blame for whether the fault lies with Tyler or with Assessor Fritz Kaegi, Treasurer Maria Pappas or Clerk Monica Gordon, the three county officeholders who handle property taxes. The family of slain Chicago police Officer Krystal Rivera is calling for city agencies to relinquish the investigation of her death and, instead, turn over the probe to the Illinois State Police as they pursue legal avenues. The slain officer's parents and their attorney also asked that the city release the body-worn camera footage that captured the fatal June 5 shooting — despite a standing order from a Cook County judge preventing the public release. A jury found a former Chicago Public Schools dean guilty of multiple felony counts for sexually abusing a student, after the young woman testified that he coerced her into a relationship years earlier while she attended a Little Village high school. For the first time in nearly 90 years, the Chicago Cubs will have two outfielders in the starting lineup at the All-Star Game. Center fielder Pete Crow-Armstrong and right fielder Kyle Tucker earned enough votes in the second phase of the process, which ran from Monday until 11 a.m. yesterday, to be named National League starters for the Midsummer Classic on July 15 at Truist Park in Atlanta. Sean 'Diddy' Combs was convicted yesterday of prostitution-related offenses under the federal Mann Act, an anti-sex trafficking law with a controversial, century-old history. Here's what to know about the law. The longest, strangest trip embarked upon by a rock 'n' roll band ended 30 years ago this week at Soldier Field. On July 9, 1995, the Grateful Dead played what would be its final concert with its full lineup at the stadium — the harmonious echoes of 'Box of Rain' concluding a fascinating musical journey that began in May 1965 at a small pizza parlor in California and encompassed more than 2,300 shows. This will be a great big for many of you, particularly armchair architecture historians, professional historians and anyone who ever took an architecture boat tour and now has strong opinions about bricks — but Christopher Borrelli didn't really know why the Wrigley gave off such odd vibes until he read 'The Wrigley Building: The Making of an Icon,' a fascinating and pretty entertaining new $95 coffee table book devoted to this terra cotta mainstay.
Yahoo
an hour ago
- Yahoo
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
Amgen recently released the full data from a trial involving its GLP-1 drug, MariTide. More than one-quarter of the participants on the highest dosage of the drug had to stop taking it due to adverse side effects. 10 stocks we like better than Amgen › There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk. But it could get much more crowded in the future. And it's little wonder why, given analysts project that the obesity drug market could be worth $200 billion by 2031. It's a mammoth growth opportunity that can jump-start a company's sales and profits. Before drugs are approved, investors can gain insights into just how promising a GLP-1 drug is from the results of clinical trials. One drug I've been keeping a close eye on, MariTide, comes from Amgen (NASDAQ: AMGN). Unlike the current products on the market which require weekly injections, Amgen's MariTide is taken monthly, and it has the potential to be a much more attractive option for patients. But its recent results were a concern. And they could end up giving investors more of a reason to invest in Eli Lilly and Novo Nordisk instead. Prior to these recent clinical trial results, I was optimistic that MariTide could make Amgen an underrated stock to own. Patients having just a monthly injection which might yield similar weight losses to that of drugs currently on the market would seem like it should be able to win over patients and doctors. Phase 2 trial data has shown that MariTide can help people lose around 20% of their body weight after being on it for about a year. Recently, the company released the full data from that trial, which uncovered a concern: At the highest dosage, 27% of participants stopped taking it due to gastrointestinal issues. But the company says that when the dosage was slowly increased, the discontinuation rate was less than 8%. The company will ensure patients in the Phase 3 trial, which is currently ongoing, will increase their doses in an effort to minimize side effects. How high that discontinuation rate ends up being in a larger trial could be critical for the stock. When it comes to GLP-1 treatments, these are medications that patients need to be on forever. The biggest downside with these treatments is that someone who stops taking them can end up gaining back the weight that they lost -- perhaps even more. If someone can't tolerate the treatment then there will be the inevitable temptation to select a different option, one where the side effects may not be as troublesome, even if it means more frequent injections or slightly lower weight loss. While a lot of the focus is on sheer weight gain percentage, I think the biggest winners in the GLP-1 race will be the companies whose treatments are best tolerated. An extra 5% weight loss may not be worth it if the trade-off means more severe gastrointestinal issues or other side effects. Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have set the standard thus far. MariTide isn't approved, but even if it is, if it doesn't shake concerns related to side effects, then there may not be strong demand for it. Amgen was looking like a potentially underrated growth stock to buy given the potential for MariTide. It still has a good business and MariTide may recover, but based on this recent data, I'd take a wait-and-see approach with the stock for the time being. The GLP-1 opportunities are what made it a compelling investment, but now, amid the question marks around MariTide, the bullish case just isn't that strong anymore. If you're looking for a top healthcare stock to buy that has much more upside in GLP-1, then going with Eli Lilly or Novo Nordisk can make much more sense at this stage. They have solid, proven products that are already approved in the space, and their share prices could end up rallying on this news. Before you buy stock in Amgen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amgen wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $722,181!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $968,402!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 David Jagielski has positions in Novo Nordisk. The Motley Fool has positions in and recommends Amgen. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk was originally published by The Motley Fool Sign in to access your portfolio
